Galmed Pharmaceuticals Reports Q3 Loss of $1.9mln, Highlights Pipeline Progress
ByAinvest
Friday, Nov 28, 2025 9:46 am ET1min read
GLMD--
Galmed Pharmaceuticals reported a Q3 loss of $1.9mln, down from $1.91mln in Q3 2024. The company highlighted progress in its pipeline programs, including Aramchol Meglumine for nonalcoholic steatohepatitis (NASH) and fibrosis, and Amilo-5MER for chronic inflammatory diseases. Research and development expenses rose to $1.1mln from $0.7mln a year earlier, while general and administrative expenses decreased to $1.0mln from $1.3mln. The stock is currently trading at $0.88, down 3.71%.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet